Assignee
INHIBRX INC
US·23 granted patents·11 pending applications·50 citations·filing 2015–2023
Top patents by PatentIndex Score
34 records- 0196US10723785B2Serpin fusion polypeptides and methods of use thereofINHIBRX INC·Filed 2018·Granted Jul 28, 2020·9 cites·15 claims
- 0293US10730929B2Serpin fusion polypeptides and methods of use thereofINHIBRX INC·Filed 2015·Granted Aug 4, 2020·5 cites·15 claims
- 0392US11866507B2Multispecific polypeptide constructs having constrained CD3 binding and methods of using the sameINHIBRX INC·Filed 2018·Granted Jan 9, 2024·8 cites·10 claims
- 0491US10526397B2Non-immunogenic single domain antibodiesINHIBRX INC·Filed 2016·Granted Jan 7, 2020·10 cites·24 claims
- 0588US10501551B2Multivalent and multispecific 41BB-binding fusion proteinsINHIBRX INC·Filed 2017·Granted Dec 10, 2019·7 cites·64 claims
- 0687US11560428B2CD33-binding polypeptides and uses thereofINHIBRX INC·Filed 2020·Granted Jan 24, 2023·2 cites·37 claims
- 0784US11117972B2Multivalent and multispecific OX40-binding fusion proteinsINHIBRX INC·Filed 2019·Granted Sep 14, 2021·2 cites·20 claims
- 0884US10093742B2Multispecific GITR-binding fusion proteins and methods of use thereofINHIBRX INC·Filed 2016·Granted Oct 9, 2018·4 cites·57 claims
- 0983US10308720B2Multivalent and multispecific DR5-binding fusion proteinsINHIBRX INC·Filed 2016·Granted Jun 4, 2019·3 cites·24 claims
- 1078US12012459B2OX40-binding polypeptides and uses thereofINHIBRX INC·Filed 2022·Granted Jun 18, 2024·0 cites·39 claims
- 1176US11976126B2Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cellsINHIBRX INC·Filed 2021·Granted May 7, 2024·0 cites·24 claims
- 1276US11965017B2Serpin fusion polypeptides and methods of use thereofINHIBRX INC·Filed 2020·Granted Apr 23, 2024·0 cites·5 claims
- 1374US11827691B2Serpin fusion polypeptides and methods of use thereofINHIBRX INC·Filed 2020·Granted Nov 28, 2023·0 cites·11 claims
- 1473US2024166744A1Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereofINHIBRX INC·Filed 2023·Application pending·0 cites
- 1573US2024101704A1Multispecific polypeptide constructs having constrained cd3 binding and methods of using the sameINHIBRX INC·Filed 2023·Application pending·0 cites
- 1672US11945869B2PD-1 single domain antibodies and therapeutic compositions thereofINHIBRX INC·Filed 2021·Granted Apr 2, 2024·0 cites·17 claims
- 1772US11208485B2PD-1 single domain antibodies and therapeutic compositions thereofINHIBRX INC·Filed 2019·Granted Dec 28, 2021·0 cites·28 claims
- 1871US11566078B2PDL1-binding proteinsINHIBRX INC·Filed 2019·Granted Jan 31, 2023·0 cites·22 claims
- 1971US2021317205A1Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereofINHIBRX INC·Filed 2021·Application pending·0 cites
- 2070US11447556B2OX40-binding polypeptides and uses thereofINHIBRX INC·Filed 2019·Granted Sep 20, 2022·0 cites·60 claims
- 2170US11117973B2Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasmsINHIBRX INC·Filed 2019·Granted Sep 14, 2021·0 cites·39 claims
- 2269US2022324944A1Serpin fusion polypeptides and methods of use thereofINHIBRX INC·Filed 2021·Application pending·0 cites
- 2366US11919963B2CD123-binding polypeptides and uses thereofINHIBRX INC·Filed 2022·Granted Mar 5, 2024·0 cites·28 claims
- 2466US2020140525A1Non-Immunogenic Single Domain AntibodiesINHIBRX INC·Filed 2019·Application pending·0 cites
- 2566US2023364208A1Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subjectINHIBRX INC·Filed 2023·Application pending·0 cites
- 2665US10745466B2Type III secretion system targeting moleculesINHIBRX INC·Filed 2019·Granted Aug 18, 2020·0 cites·33 claims
- 2763US10844129B2Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acidsINHIBRX INC·Filed 2018·Granted Nov 24, 2020·0 cites·34 claims
- 2861US2019330366A1Multispecific polypeptide constructs having constrained cd3 binding and related methods and usesINHIBRX INC·Filed 2019·Application pending·0 cites
- 2959US11434297B2CD123-binding polypeptides and uses thereofINHIBRX INC·Filed 2020·Granted Sep 6, 2022·0 cites·30 claims
- 3058US2024376198A1NKp46-Targeted Modified IL-2 Polypeptides and Uses ThereofINHIBRX INC·Filed 2022·Application pending·0 cites
- 3155US2023331846A1Canine PD-1-Binding Polypeptides and Uses ThereofINHIBRX INC·Filed 2021·Application pending·0 cites
- 3255US2023235005A1Polypeptides Comprising Modified IL-2 Polypeptides and Uses ThereofINHIBRX INC·Filed 2021·Application pending·0 cites
- 3351US10344078B2Type III secretion system targeting moleculesINHIBRX INC·Filed 2016·Granted Jul 9, 2019·0 cites·19 claims
- 3449US2022089667A1Polypeptides Comprising Modified IL-2 Polypeptides and Uses ThereofINHIBRX INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when INHIBRX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →